UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood, 2024-08, Vol.144 (5), p.510-524

2024

Volltextzugriff (PDF)

Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application

Haematologica (Roma), 2024-05, Vol.109 (5), p.1348

2024

Volltextzugriff (PDF)

Abstract 5828: The genomic architecture of ibrutinib resistance in CLL: Oligoclonal progression with variable anatomical distribution

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5828-5828

2024

Volltextzugriff (PDF)

Genomic risk stratification in chronic lymphocytic leukemia

Clinical advances in hematology & oncology : H&O, 2024, Vol.22 (1), p.6-8

Wiestner, Adrian

2024

Volltextzugriff (PDF)

Genomic risk stratification in chronic lymphocytic leukemia

Clinical advances in hematology & oncology, 2024-01, Vol.22 (1), p.6

Wiestner, Adrian

2024

Volltextzugriff (PDF)

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL

Leukemia & lymphoma, 2023-12, Vol.64 (14), p.2306-2315

2023

Volltextzugriff (PDF)

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Blood, 2023-11, Vol.142 (Supplement 1), p.1891-1891

2023

Volltextzugriff (PDF)

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Blood, 2023-11, Vol.142 (Supplement 1), p.4463-4463

2023

Volltextzugriff (PDF)

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Blood, 2023-11, Vol.142 (Supplement 1), p.4196-4196

2023

Volltextzugriff (PDF)

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.201-201

2023

Volltextzugriff (PDF)

Surface Chemistry Dictates the Osteogenic and Antimicrobial Properties of Palladium‐, Platinum‐, and Titanium‐Based Bulk Metallic Glasses

Advanced functional materials, 2023-11, Vol.33 (48), p.n/a

2023

Volltextzugriff (PDF)

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Clinical cancer research, 2023-09, Vol.29 (18), p.3612-3621

2023

Volltextzugriff (PDF)

CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy

Clinical cancer research, 2023-09, Vol.29 (18), p.3612-3621

2023

Volltextzugriff (PDF)

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Clinical cancer research, 2023-08, Vol.29 (16), p.3065-3073

2023

Volltextzugriff (PDF)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Blood advances, 2023-08, Vol.7 (15), p.4089-4101

2023

Volltextzugriff (PDF)

Vibrio-Sequins - dPCR-traceable DNA standards for quantitative genomics of Vibrio spp

BMC genomics, 2023-07, Vol.24 (1), p.375-375, Article 375

2023

Volltextzugriff (PDF)

Splenic Size and Volume Measurements in Patients with Chronic Lymphocytic Leukemia

Academic radiology, 2023-06, Vol.30 (6), p.1056-1065

2023

Volltextzugriff (PDF)

Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL

Hematological oncology, 2023-06, Vol.41 (S2), p.570-571

2023

Volltextzugriff (PDF)

Combination immunotherapy of ibrutinib, fludarabine, and pembrolizumab for high-risk CLL patients: clinical and immunological analysis of a pilot phase II study

The Journal of immunology (1950), 2023-05, Vol.210 (1_Supplement), p.68-68.09

2023

Volltextzugriff (PDF)

Abstract 4100: Co-stimulatory signaling boosts CAR T cell efficacy against chronic lymphocytic leukemia

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4100-4100

2023

Volltextzugriff (PDF)

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Blood, 2023-03, Vol.141 (13), p.1584-1596

2023

Volltextzugriff (PDF)

The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia

Blood advances, 2023-01, Vol.7 (1), p.145-158

2023

Volltextzugriff (PDF)

Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia

British journal of haematology, 2023-01, Vol.200 (2), p.261-263

2023

Volltextzugriff (PDF)

Ibrutinib-Associated Sudden Death in Patients with CLL

Blood, 2022-11, Vol.140 (Supplement 1), p.4133-4134

2022

Volltextzugriff (PDF)

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.6004-6005

2022

Volltextzugriff (PDF)

1 – 25 von 467

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(438)
Mit Volltextzugriff
(404)

Publikationsform

Sprache

Englisch
(463)
Japanisch
(37)
Deutsch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(237)
Life Sciences & Biomedicine
(223)
Humans
(177)
Hematology
(104)
Animals
(79)
Female
(79)
Oncology
(79)
Male
(78)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(74)
Aged
(56)
Chronic Lymphocytic Leukemia
(54)
Middle Aged
(51)
Biological And Medical Sciences
(41)
Medical Sciences
(40)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(37)
Leukemia, Lymphocytic, Chronic, B-Cell - Pathology
(37)
Veterinary Sciences
(36)
Adult
(34)
Mutation
(34)
Hematologic And Hematopoietic Diseases
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(165)
Clinical Cancer Research
(24)
Leukemia & Lymphoma
(20)
Cancer Research
(17)
Haematologica
(13)
British Journal Of Haematology
(12)
Equine Veterinary Journal
(12)
Leukemia & Lymphoma/leukemia And Lymphoma
(12)
The Journal Of Immunology
(12)
Clinical Lymphoma, Myeloma And Leukemia
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application

Abstract 5828: The genomic architecture of ibrutinib resistance in CLL: Oligoclonal progression with variable anatomical distribution

Genomic risk stratification in chronic lymphocytic leukemia

Genomic risk stratification in chronic lymphocytic leukemia

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Surface Chemistry Dictates the Osteogenic and Antimicrobial Properties of Palladium‐, Platinum‐, and Titanium‐Based Bulk Metallic Glasses

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Vibrio-Sequins - dPCR-traceable DNA standards for quantitative genomics of Vibrio spp

Splenic Size and Volume Measurements in Patients with Chronic Lymphocytic Leukemia

Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL

Combination immunotherapy of ibrutinib, fludarabine, and pembrolizumab for high-risk CLL patients: clinical and immunological analysis of a pilot phase II study

Abstract 4100: Co-stimulatory signaling boosts CAR T cell efficacy against chronic lymphocytic leukemia

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia

Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia

Ibrutinib-Associated Sudden Death in Patients with CLL

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Suchergebnisse filtern